Back

Delay Differential Equation (DDE) Modeling of CAR-T Cellular Kinetics: Application to BCMA-Targeted (Ide-cel, Orva-cel) and CD19-Targeted (Liso-cel) Therapies

Li, Y.; Cheng, Y.

2026-03-03 pharmacology and toxicology
10.64898/2026.03.01.708830 bioRxiv
Show abstract

Chimeric antigen receptor (CAR) T-cell therapies undergo rapid in vivo expansion followed by contraction and variable long-term persistence after a single infusion, yielding cellular kinetic (CK) profiles that differ fundamentally from conventional small-molecule and biologic pharmacokinetics. Piecewise, phase-based CK models are widely used, but discontinuous switching and constant expansion assumptions can create numerical instability around the transition window and bias the characterization of early expansion and near-peak behavior. Building on our prior saturable expansion framework (Vmax/Km), we advanced CAR-T CK modeling by introducing (i) smooth S-shaped gating to replace discontinuous phase switching and enable continuous time-varying expansion dynamics, and (ii) delay differential equation (DDE) components to evaluate whether longitudinal data support explicit lags in downstream biological processes. Data were pooled from three CAR-T trials (TRANSCEND, KarMMa-3, and EVOLVE) spanning two BCMA-targeted products (ide-cel, orva-cel) and one CD19-targeted product (liso-cel). Models were estimated in Monolix using SAEM with importance sampling for final likelihood evaluation. Model selection relied on likelihood-based criteria (AIC, BIC, and Monolix BICc) and diagnostic assessments. Relative to a constant-expansion baseline, saturable expansion improved fit and reduced systematic model misspecification at high transgene levels (e.g., qPCR transgene copies/{micro}g). Among multiple DDE placements evaluated, the data most strongly supported a delay on effector-to-memory conversion; delays in effector-like and/or memory-like decay were not favored. Simulations indicated that the conversion delay primarily modulated the timing and magnitude of the memory-like trajectory, with minimal impact on total-cell trajectories during the expansion phase at the evaluated scale. In a shared covariate framework with product as a categorical effect, BCMA-targeted products exhibited higher baseline levels and expansion capacity than liso-cel, with stronger evidence for slower effector-like decay for orva-cel than ide-cel. Overall, smooth-gated saturable expansion with DDE-based delayed conversion provides a parsimonious, biologically motivated framework for CAR-T CK and supports cross-product comparisons under harmonized structural assumptions.

Matching journals

The top 13 journals account for 50% of the predicted probability mass.

1
PLOS Computational Biology
1633 papers in training set
Top 4%
8.5%
2
Clinical Pharmacology & Therapeutics
25 papers in training set
Top 0.1%
6.5%
3
eLife
5422 papers in training set
Top 13%
6.4%
4
PLOS ONE
4510 papers in training set
Top 33%
4.4%
5
Nature Communications
4913 papers in training set
Top 37%
4.0%
6
Journal of Controlled Release
39 papers in training set
Top 0.3%
3.9%
7
ACS Pharmacology & Translational Science
40 papers in training set
Top 0.1%
3.6%
8
Frontiers in Pharmacology
100 papers in training set
Top 0.9%
3.6%
9
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 27%
2.1%
10
mAbs
28 papers in training set
Top 0.1%
2.1%
11
JCI Insight
241 papers in training set
Top 3%
1.9%
12
Scientific Reports
3102 papers in training set
Top 53%
1.9%
13
Nature Machine Intelligence
61 papers in training set
Top 2%
1.9%
50% of probability mass above
14
Communications Biology
886 papers in training set
Top 6%
1.9%
15
Antibody Therapeutics
16 papers in training set
Top 0.2%
1.9%
16
npj Systems Biology and Applications
99 papers in training set
Top 1.0%
1.8%
17
Science Translational Medicine
111 papers in training set
Top 2%
1.7%
18
Clinical and Translational Science
21 papers in training set
Top 0.4%
1.7%
19
Circulation
66 papers in training set
Top 2%
1.7%
20
Computational and Structural Biotechnology Journal
216 papers in training set
Top 4%
1.7%
21
AIDS
31 papers in training set
Top 0.3%
1.7%
22
Molecular Pharmaceutics
16 papers in training set
Top 0.3%
1.5%
23
Science Advances
1098 papers in training set
Top 21%
1.3%
24
Nature Biomedical Engineering
42 papers in training set
Top 1%
1.3%
25
Journal of Medicinal Chemistry
68 papers in training set
Top 0.8%
1.3%
26
Patterns
70 papers in training set
Top 1%
1.2%
27
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
62 papers in training set
Top 1%
1.2%
28
eBioMedicine
130 papers in training set
Top 2%
1.1%
29
Cell Systems
167 papers in training set
Top 10%
0.9%
30
Bioinformatics
1061 papers in training set
Top 9%
0.8%